Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

NCT03698331 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03698331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
Lead sponsor
Neurocrine Biosciences
Phase
Phase 4
Overall status
Completed
Start date
September 14, 2018
Completion date
April 3, 2019
Enrollment
89 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia (td)